dalteparin has been researched along with Heart Disease, Ischemic in 54 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment." | 9.13 | Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. ( Johnston, N; Oldgren, J; Siegbahn, A, 2008) |
| " All of them concomitantly received 100 mg/day aspirin because of previous ischaemic heart disease and presented similar clinical features: sudden onset of abdominal pain during a severe cough episode due to bronchial infection." | 7.73 | Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks. ( Gonzalez-Ordonez, AJ; Macías-Robles, MD; Peliz, MG, 2005) |
| "We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment." | 5.13 | Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. ( Johnston, N; Oldgren, J; Siegbahn, A, 2008) |
| "The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)." | 5.12 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006) |
| "In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin." | 5.12 | Bivalirudin for patients with acute coronary syndromes. ( Aylward, PE; Bertrand, ME; Cequier, AR; Colombo, A; Cox, DA; Darius, H; Desmet, W; Ebrahimi, R; Feit, F; Hamon, M; Hoekstra, J; Lincoff, AM; McLaurin, BT; Mehran, R; Moses, JW; Ohman, EM; Pocock, SJ; Rasmussen, LH; Rupprecht, HJ; Stone, GW; Ware, JH; White, HD, 2006) |
| "The OASIS-5 trial is a randomized, double-blind trial of fondaparinux versus enoxaparin in 20,000 patients with unstable angina or non-ST-segment elevation myocardial infarction." | 5.11 | Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. ( Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2005) |
| " All of them concomitantly received 100 mg/day aspirin because of previous ischaemic heart disease and presented similar clinical features: sudden onset of abdominal pain during a severe cough episode due to bronchial infection." | 3.73 | Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks. ( Gonzalez-Ordonez, AJ; Macías-Robles, MD; Peliz, MG, 2005) |
| " During UFH-anticoagulated HD 75% VEGF(165) decrease after 10min was negatively associated with heparin dosage and was more profound in patients with ischemic heart disease." | 2.73 | Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study. ( Myśliwiec, M; Naumnik, B; Pawlak, K, 2007) |
| "Rates of myocardial infarction were 141 (12." | 2.72 | 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. ( Husted, S; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2006) |
| "Minor bleeding was more frequent in the enoxaparin group (30." | 2.71 | Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003) |
| "Prospective, randomized, double-blind study (POLENOX) proved that administration of low molecular weight heparin (LMWH)--enoxaparin for elective percutaneous coronary interventions (PCI) is as safe and as effective like unfractionated heparin (UFH)." | 2.71 | [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine]. ( Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Legutko, J; Rzeszutko, L, 2004) |
| " Due to a longer plasma half life together with high bioavailability and a linear dose-response relationship, the drugs can be safely and effectively administered in the hospital or ambulatory settings without the need to monitor the anticoagulant effect." | 2.42 | Clinical application of enoxaparin. ( Hofmann, T, 2004) |
| "Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality." | 2.41 | Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. ( Adgey, AA; Manoharan, G, 2002) |
| "Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug has to alter the effects of another when both are administered simultaneously." | 1.56 | Potential drug-drug interactions in ICU patients: a retrospective study. ( Ali, I; Bazzar, A; Hussein, N; Sahhar, E, 2020) |
| "Unfractionated heparin (UFH) has been considered the standard anticoagulant for patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS), yet it has limitations, including an unpredictable dose-response and intravenous administration." | 1.33 | Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. ( Goodman, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (12.96) | 18.2507 |
| 2000's | 43 (79.63) | 29.6817 |
| 2010's | 3 (5.56) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Faĭl', IL | 1 |
| Dolgikh, VT | 1 |
| Morova, NA | 1 |
| Kireeva, NV | 1 |
| Smirnov, DE | 1 |
| Kovaleva, SV | 1 |
| Conti, CR | 1 |
| Ali, I | 1 |
| Bazzar, A | 1 |
| Hussein, N | 1 |
| Sahhar, E | 1 |
| Öztürk, S | 1 |
| Can, I | 1 |
| Erden, I | 1 |
| Akyol, H | 1 |
| Solmaz, OA | 1 |
| Cygan, LD | 1 |
| Weizberg, M | 1 |
| Hahn, B | 1 |
| Somani, V | 1 |
| Trivedi, S | 1 |
| Brener, SJ | 1 |
| Bhatt, DL | 1 |
| Hamon, M | 3 |
| Rasmussen, LH | 2 |
| Manoukian, SV | 2 |
| Cequier, A | 1 |
| Lincoff, MA | 1 |
| Rupprecht, HJ | 2 |
| Gersh, BJ | 1 |
| Mann, T | 1 |
| Bertrand, ME | 3 |
| Mehran, R | 4 |
| Stone, GW | 5 |
| Rao, SV | 1 |
| Ohman, EM | 4 |
| Tang, AT | 1 |
| Kalra, PR | 1 |
| Calver, AL | 1 |
| Monro, JL | 1 |
| Uzan, A | 2 |
| Goodman, SG | 4 |
| Fitchett, D | 1 |
| Armstrong, PW | 1 |
| Tan, M | 1 |
| Langer, A | 4 |
| Collet, JP | 2 |
| Montalescot, G | 4 |
| Fine, E | 1 |
| Golmard, JL | 2 |
| Dalby, M | 1 |
| Choussat, R | 2 |
| Ankri, A | 2 |
| Dumaine, R | 1 |
| Lesty, C | 1 |
| Vignolles, N | 2 |
| Thomas, D | 2 |
| Tanguy, ML | 1 |
| Beygui, F | 1 |
| Drobinski, G | 1 |
| Hofmann, T | 1 |
| Das, P | 1 |
| Moliterno, DJ | 2 |
| Exaire, JE | 1 |
| Tcheng, JE | 1 |
| Kereiakes, DJ | 1 |
| Kleiman, NS | 2 |
| Applegate, RJ | 1 |
| Macías-Robles, MD | 1 |
| Peliz, MG | 1 |
| Gonzalez-Ordonez, AJ | 1 |
| Mahaffey, KW | 2 |
| Ferguson, JJ | 2 |
| Goodman, S | 2 |
| Cohen, M | 6 |
| Garg, J | 1 |
| Antman, E | 1 |
| Berdan, LG | 1 |
| Reist, CJ | 1 |
| White, HD | 6 |
| Aylward, PE | 4 |
| Col, JJ | 1 |
| Califf, RM | 3 |
| Mehta, SR | 1 |
| Yusuf, S | 1 |
| Granger, CB | 1 |
| Wallentin, L | 3 |
| Peters, RJ | 1 |
| Bassand, JP | 1 |
| Budaj, A | 1 |
| Joyner, C | 1 |
| Chrolavicius, S | 1 |
| Fox, KA | 4 |
| Schreiber, R | 1 |
| Gibson, CM | 1 |
| Morrow, DA | 1 |
| Murphy, SA | 1 |
| Palabrica, TM | 1 |
| Jennings, LK | 1 |
| Stone, PH | 1 |
| Lui, HH | 1 |
| Bulle, T | 1 |
| Lakkis, N | 1 |
| Kovach, R | 1 |
| Cohen, DJ | 1 |
| Fish, P | 1 |
| McCabe, CH | 2 |
| Braunwald, E | 2 |
| Gallo, R | 2 |
| Steg, PG | 2 |
| Bode, C | 1 |
| Chiariello, M | 1 |
| King, SB | 1 |
| Harrington, RA | 1 |
| Desmet, WJ | 2 |
| Macaya, C | 2 |
| Steinhubl, SR | 2 |
| O'Neill, WW | 1 |
| McLaurin, BT | 2 |
| Cox, DA | 2 |
| Lincoff, AM | 3 |
| Moses, JW | 2 |
| Pocock, SJ | 2 |
| Ware, JH | 2 |
| Feit, F | 3 |
| Colombo, A | 2 |
| Cequier, AR | 1 |
| Darius, H | 1 |
| Desmet, W | 1 |
| Ebrahimi, R | 1 |
| Hoekstra, J | 1 |
| Bhala, N | 1 |
| Schuler, J | 1 |
| Altenberger, J | 1 |
| Heigert, M | 1 |
| Pasceri, V | 1 |
| Riddell, JW | 1 |
| Karthikeyan, G | 1 |
| Lansky, AJ | 1 |
| Naumnik, B | 1 |
| Pawlak, K | 1 |
| Myśliwiec, M | 1 |
| Nutescu, EA | 1 |
| Steinmetz Pater, K | 1 |
| Salette, G | 1 |
| Chew, DP | 1 |
| Hoekstra, JW | 1 |
| Miller, CD | 1 |
| Pollack, CV | 1 |
| Bertrand, M | 1 |
| Pocock, S | 1 |
| Ware, J | 1 |
| Antman, EM | 1 |
| Sacks, DB | 1 |
| Rifai, N | 1 |
| Cannon, CP | 1 |
| Libersan, D | 1 |
| Khalil, A | 1 |
| Dagenais, P | 1 |
| Quan, E | 1 |
| Delorme, F | 1 |
| Latour, JG | 1 |
| Demers, C | 1 |
| Gurfinkel, EP | 3 |
| Turpie, AG | 2 |
| Fromell, GJ | 3 |
| Premmereur, J | 1 |
| Bigonzi, F | 1 |
| Zidar, JP | 1 |
| Stinnett, SS | 1 |
| Weatherley, BD | 1 |
| Santopinto, J | 1 |
| Bozovich, GE | 1 |
| Quispe, A | 1 |
| Strinna, A | 1 |
| Mautner, B | 1 |
| Barr, A | 1 |
| Sobtchouk, A | 1 |
| Laperrière, L | 1 |
| Hill, C | 1 |
| Kiesz, RS | 1 |
| Buszman, P | 1 |
| Martin, JL | 1 |
| Deutsch, E | 1 |
| Rozek, MM | 1 |
| Gaszewska, E | 1 |
| Rewicki, M | 1 |
| Seweryniak, P | 1 |
| Kosmider, M | 1 |
| Tendera, M | 1 |
| Pechlaner, C | 1 |
| Gritsch, W | 1 |
| Wiedermann, C | 1 |
| Mason, JA | 1 |
| Diderholm, E | 1 |
| Andrén, B | 1 |
| Frostfeldt, G | 1 |
| Genberg, M | 1 |
| Jernberg, T | 1 |
| Lagerqvist, B | 2 |
| Lindahl, B | 1 |
| Manoharan, G | 1 |
| Adgey, AA | 1 |
| Dudek, D | 1 |
| Chyrchel, M | 1 |
| Legutko, J | 1 |
| Bartuś, S | 1 |
| Rzeszutko, L | 1 |
| Dubiel, JS | 1 |
| Husted, S | 1 |
| Kontny, F | 1 |
| Ståhle, E | 1 |
| Swahn, E | 1 |
| Oldgren, J | 1 |
| Johnston, N | 1 |
| Siegbahn, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes[NCT00552513] | 3,031 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Per[NCT00077844] | Phase 2/Phase 3 | 3,532 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| Early Re-Endothelialization Might Not be the Unique Solution to Prevent Restenosis. The EREMUS Study[NCT00870038] | Phase 4 | 75 participants (Anticipated) | Interventional | 2010-12-31 | Not yet recruiting | ||
| Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin[NCT01931852] | 312 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Acute Angioplasty (Primary PCI) Versus Traditional Early Invasive Treatment of Patients Presenting With NSTEMI (The Second Danish Non-ST-Elevation MI Trial - DaNSTEMI-2)[NCT00493584] | 14 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Due to insufficient patient inclusion the study has been stopped prematurely.) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00552513)
Timeframe: 180 days
| Intervention | Eparticipants (Number) |
|---|---|
| Early Intervention | 264 |
| Delayed Intervention | 280 |
(NCT00552513)
Timeframe: 180 days
| Intervention | participants (Number) |
|---|---|
| Early Intervention | 153 |
| Delayed Intervention | 163 |
(NCT00552513)
Timeframe: 180 days
| Intervention | participants (Number) |
|---|---|
| Early Intervention | 151 |
| Delayed Intervention | 186 |
8 reviews available for dalteparin and Heart Disease, Ischemic
| Article | Year |
|---|---|
Spontaneous, resolving S1Q3T3 in pulmonary embolism: A case report and literature review on prognostic value of electrocardiography score for pulmonary embolism.
Topics: Adult; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Humans; Male; Myocardial Ischem | 2016 |
Anticoagulant therapy for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as Topic; Coronary Th | 2010 |
[Thrombosis and ischemia: experimental data].
Topics: Animals; Apoptosis; Coronary Thrombosis; Disease Models, Animal; Dogs; Enoxaparin; Fibrinolytic Agen | 2002 |
Clinical application of enoxaparin.
Topics: Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Ag | 2004 |
Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.
Topics: Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Enoxaparin; Health Care Costs; Huma | 2008 |
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Death, Sudden, Cardiac; Enox | 1999 |
Review of enoxaparin and its clinical applications in venous and arterial thromboembolism.
Topics: Anticoagulants; Biological Availability; Drug Evaluation; Economics, Pharmaceutical; Enoxaparin; Hal | 2002 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic | 2002 |
23 trials available for dalteparin and Heart Disease, Ischemic
| Article | Year |
|---|---|
Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2009 |
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal | 2003 |
Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Enoxaparin; | 2005 |
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Topics: Enoxaparin; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Mortality; Myocardial Infarctio | 2005 |
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Double-Blind Method; Enoxap | 2005 |
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Bivalirudin for patients with acute coronary syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Co | 2006 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Th | 2007 |
Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cross-Over Studies; Endothelium, Vascular; Enoxapari | 2007 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgen
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heart C | 2008 |
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow- | 1998 |
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Administration Routes; D | 1998 |
Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Fem | 1998 |
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi | 2000 |
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Fema | 2000 |
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.
Topics: Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Stud | 2000 |
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
Topics: Anticoagulants; Aspirin; Drug Administration Routes; Drug Delivery Systems; Enoxaparin; Female; Foll | 2001 |
Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease.
Topics: Angina, Unstable; Coronary Angiography; Dalteparin; Exercise Test; Exercise Tolerance; Female; Fibri | 2003 |
[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dal | 2004 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Topics: Acute Disease; Aged; Anticoagulants; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug | 2008 |
23 other studies available for dalteparin and Heart Disease, Ischemic
| Article | Year |
|---|---|
[Changes in coagulation hemostasis in patients after coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Blood Coagulation Disorders; Coronary Artery Bypass; Fibrin Fibrinogen Degr | 2008 |
Low molecular weight heparin for acute ischemic heart disease.
Topics: Acute Disease; Anticoagulants; Clinical Trials as Topic; Dalteparin; Drug Administration Routes; Ele | 1997 |
Potential drug-drug interactions in ICU patients: a retrospective study.
Topics: Aspirin; Diabetes Mellitus; Drug Interactions; Enoxaparin; Hospitalization; Humans; Hypertension; In | 2020 |
Enoxaparin-induced hemorrhagic bullous dermatosis in a leprosy patient.
Topics: Aged; Anticoagulants; Enoxaparin; Humans; Leprosy; Male; Myocardial Ischemia; Skin Diseases, Vesicul | 2015 |
Enoxaparin experience in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; | 2008 |
The pain and the gain of treating patients with acute coronary syndromes-can the two be separated?
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Is | 2009 |
Enoxaparin in unstable ischemic heart disease: friend or foe?
Topics: Anticoagulants; Enoxaparin; Female; Humans; Middle Aged; Myocardial Ischemia; Treatment Outcome | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath | 2004 |
Fractionating heparins and their clinical trial data--something for everyone.
Topics: Angina Pectoris; Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infa | 2004 |
Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks.
Topics: Abdominal Wall; Aged; Aged, 80 and over; Aspirin; Cough; Dose-Response Relationship, Drug; Drug Ther | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
Topics: Acute Disease; Anticoagulants; Arrhythmias, Cardiac; Enoxaparin; Eptifibatide; Heparin; Humans; Myoc | 2005 |
Low-molecular-weight heparin vs unfractionated heparin in acute coronary syndromes.
Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Myocardial Ischemia; Partial Thromboplastin Time | 2006 |
Risk of bleeding after elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Cause of Death; Enoxaparin; Hemorrhage; Heparin; Hum | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Protocols; Enoxaparin; Hemorrhage; Heparin; | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial | 2006 |
The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog.
Topics: Analysis of Variance; Animals; Anticoagulants; Blood Platelets; Cells, Cultured; Dogs; Enoxaparin; E | 1998 |
Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
Topics: Abciximab; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Enoxaparin for acute coronary syndromes?
Topics: Acute Disease; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Ischemia; Syndrome | 2001 |